Cancer Institute A national cancer institute
designated cancer center

Dean W. Felsher

Publication Details

  • Reversible tumorigenesis by MYC in hematopoietic lineages MOLECULAR CELL Felsher, D. W., BISHOP, J. M. 1999; 4 (2): 199-207

    Abstract:

    The targeted repair of mutant protooncogenes or the inactivation of their gene products may be a specific and effective therapy for human neoplasia. To examine this possibility, we have used the tetracycline regulatory system to generate transgenic mice that conditionally express the MYC protooncogene in hematopoietic cells. Sustained expression of the MYC transgene culminated in the formation of malignant T cell lymphomas and acute myleoid leukemias. The subsequent inactivation of the transgene caused regression of established tumors. Tumor regression was associated with rapid proliferative arrest, differentiation and apoptosis of tumor cells, and resumption of normal host hematopoiesis. We conclude that even though tumorigenesis is a multistep process, remediation of a single genetic lesion may be sufficient to reverse malignancy.

    View details for Web of Science ID 000082387700006

    View details for PubMedID 10488335

Stanford Medicine Resources:

Footer Links: